Health & Biotech
Stock Insiders: Bone healing company Osteopore is regenerating bones with 3D-printed scaffold system
Health & Biotech
ASX Health Stocks: ResApp jumps 65pc on smartphone Covid-19 cough tests
Health & Biotech
Similarities with our pets could offer giant breakthroughs in cancer research, says PharmAust
Health & Biotech
ASX Health Stocks: TGA gives Orthocell green light for its nerve repair device Remplir
Health & Biotech
Wellnex shares take flight on epic GlaxoSmithKline deal
Health & Biotech
ASX Health Stocks: ImpediMed extends SOZO contract with global pharma AstraZeneca
Health & Biotech
Gastrointerest: How EZZ is working to get us all a healthy digestive system
Health & Biotech
4D Medical CEO hails launch of world’s first dedicated lung scanner, stock price jumps 30pc
Health & Biotech
SKN delivers hundreds of thousands of litres of its Covid-killing, plant-based, TGA-backed ‘SuprCuvr’ as latest deal pays off
Health & Biotech
Check Up: Gloomy days for biotechs, but there were significant moves on the ASX this week
Health & Biotech
Singular’s additive manufacturing investment is bearing fruit
Health & Biotech
PharmAust ships first batch of MPL to the US, gets ready for two upcoming clinical trials
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.